Research programme: pain therapeutics - PhytoPain Pharma

Drug Profile

Research programme: pain therapeutics - PhytoPain Pharma

Alternative Names: Cannabidiol; Delta-9-tetrahydrocannibinol; PPP-001; PPTGR

Latest Information Update: 20 Feb 2017

Price : $50

At a glance

  • Originator PhytoPain Pharma
  • Class Analgesics; Cannabinoids; Small molecules
  • Mechanism of Action Cannabinoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Neuropathic pain

Most Recent Events

  • 16 Feb 2017 Therapeutic Products Directorate, Health Canada approves clinical trial application for phase I trial of PPP 001 in Neuropathic pain (In volunteers) (Inhalation)
  • 01 Feb 2017 Therapeutic Products Directorate, Health Canada, approves clinical trial application for phase I of PPTGR in Pain (Chemotherapy-induced neuropathic pain) (Topical)
  • 30 Jan 2017 PhytoPain plans a phase I trial of PPP 001 in Healthy volunteers in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top